LISTED Australian medical life sciences company, Medlab Clinical Ltd has announced it has received a Licence to Export Cannabis from the Office of Drug Control in Canberra, specifically relating to its first two cannabis-based medicines, NanaBis and NanaBidial.
NanaBis is a whole plant 1:1 extract of CBD and THC, whilst NanaBidial is a whole plant extract of CBD and THC (predominantly CBD).
Both products utilise Medlab's patented NanoCelle delivery platform which allows the delivery of nano particles of the active pharmaceutical ingredients into the side of the cheek (buccal delivery).
Medlab announced earlier this month the preliminary results received from the University of Sydney's Nano Institute, School of Pharmacy validating the science behind the NanoCelle delivery platform.
According to Medlab ceo Dr Sean Hall, the Export Licence, which is renewable annually, allows Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the company can supply legally overseas.
"This licence is a welcome addition to our other approvals, allowing Medlab to research, manufacture, conduct research trials, supply within Australia, and now, pending the right partner, foreign markets," Hall said.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 18
